Search
Type
Audience
Category
Issue
Last updated
Recall class
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archive checkbox.
Displaying 1 - 15 of 849 items.
Amitriptyline antidepressant drugs recalled because of a nitrosamine impurity
UPDATE: February 7, 2023
One lot of APO-Amitriptyline recalled due to a nitrosamine impurity
Apotex Inc. is recalling one lot of APO-Amitriptyline (lot PY1904) 10 mg tablets due to the presence of N-nitrosodimethylamine (NDMA), a nitrosamine…
AlertPublic advisory | 2023-02-07
APO-AMITRIPTYLINE 10mg: NDMA Impurity
Affected lot exceeds concentration limit for N-nitrosodimethylamine (NDMA) at the 48-month stability testing timepoint.
RecallHealth product recall | 2023-02-07
Know the risks: Replacing a healthy natural eye lens with an intraocular eye lens for vision correction
Health Canada is warning that intraocular lenses are not licensed to replace a patient’s natural, healthy lens (without cataracts) and that their use for this purpose comes with risks that may outweigh the benefits.
Entities such as surgical eye…
AlertPublic advisory | 2023-02-03
Fiber Plus Powder: Affected lots may contain the presence of Cronobacter contamination
Affected lots may contain the presence of Cronobacter contamination.
RecallHealth product recall | 2023-02-02
Celestone Soluspan: Affected lots may contain the presence of foreign matter.
Affected lots may contain the presence of foreign matter.
RecallHealth product recall | 2023-01-31
Unauthorized products may pose serious health risks
Health Canada is advising about unauthorized health products that may pose serious health risks. The table is updated when Health Canada finds unauthorized health products that are promoted for sexual enhancement, weight loss, as a workout aid, as "…
AlertPublic advisory | 2023-01-25
RUZURGI (amifampridine) - Authorization Status
UPDATED INFORMATION – January 20, 2023
On January 10, 2023, following a Federal Court of Appeal decision, the June 24, 2021 decision of the Minister of Health on the application of the data protection provisions was restored, and a new Notice of…
AlertHealth professional risk communication | 2023-01-20
Unauthorized health products removed from sale from More to Shoppe Facebook store and its Edson, Alberta, warehouse
Health Canada removed various unauthorized health products from sale from More to Shoppe, an online Facebook store, and from its warehouse in Edson, Alberta. The products are labelled to contain prescription drugs and may pose serious health risks.…
AlertPublic advisory | 2023-01-20
Belzer MPS and Belzer UW: Particulate matter
Presence of particulate matter in affected lot.
RecallHealth product recall | 2023-01-18
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
UPDATED INFORMATION – 2023/01/17
Neutralization data for the following SARS-CoV-2 Omicron subvariants have been added to the Canadian Product Monograph: Omicron BA.2.75.2, BF.7, BJ.1, BN.1, BQ.1, BQ.1.1, and XBB. See Table 1 (below) for a summary…
AlertHealth professional risk communication | 2023-01-17
99.0 % Oxygen USP - Gas cylinders containing commercial grade oxygen
Gas cylinders containing commercial grade oxygen instead of medical grade oxygen were delivered to homecare customers.
RecallHealth product recall | 2022-12-22
Flourimax suspension: Out of specification
The concentration of the medicinal ingredient, sodium fluoride, is out of specification in the affected lot.
RecallHealth product recall | 2022-12-15
Allergenic extract non pollens (Peanut allergy): False negative for skin test
Affected lot may result in a false negative for skin test (peanut allergy).
RecallHealth product recall | 2022-12-14
18F-Fludeoxyglucose (18F-FDG); Sterility concerns
Product sterility may be compromised in the affected lot.
RecallHealth product recall | 2022-12-14
COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton Labels: New Formulation for Use in Children 5 to Less Than 12 Years of Age
On December 9, 2022, Health Canada authorized a new formulation of the bivalent vaccine, COMIRNATY Original & Omicron BA.4/BA.5, as a booster dose for active immunization against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory…
AlertHealth professional risk communication | 2022-12-09